Jun 23, 2026
CroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study
Read More
Jun 9, 2026
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
Read More
Jun 7, 2026
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a firstin- class GIPR antagonist
Download PDF
May 27, 2026
Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure
Read More
May 21, 2026
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Read More
May 20, 2026
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001
Read More
1234